<PAGE> 1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to __________
Commission file number 333-70553
HEALTHEON CORPORATION
(Exact name of Registrant as specified in its charter)
DELAWARE 94-3236644
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
4600 PATRICK HENRY DRIVE
SANTA CLARA, CALIFORNIA 95054
(Address of principal executive offices)
(408) 876-5000
(Registrant's telephone number, including area code)
-----------------
Check whether the registrant: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
YES [X] NO [ ]
As of July 31, 1999, there were 71,109,338 shares of the Registrant's
Common Stock outstanding.
================================================================================
<PAGE> 2
- --------------------------------------------------------------------------------
HEALTHEON CORPORATION
QUARTERLY REPORT ON FORM 10-Q
FOR THE PERIOD ENDED JUNE 30, 1999
INDEX
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
PAGE
PART I FINANCIAL INFORMATION NUMBER
<S> <C>
ITEM 1. Financial Statements:
Condensed Consolidated Balance Sheets as of June 30, 1999 and December 31,
1998..................................................................... 3
Condensed Consolidated Statements of Operations for the three and six months
ended June 30, 1999 and 1998............................................. 4
Condensed Consolidated Statements of Cash Flows for the six months ended June
30, 1999 and 1998........................................................ 5
Notes to Condensed Consolidated Financial Statements......................... 6
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations............................................................ 9
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk................... 22
PART II OTHER INFORMATION
ITEM 6. Exhibits and Reports on Form 8-K............................................. 23
Signatures................................................................... 24
</TABLE>
2
<PAGE> 3
- --------------------------------------------------------------------------------
PART I: FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
HEALTHEON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
<TABLE>
<CAPTION>
JUNE 30, DECEMBER 31,
1999 1998
--------- ------------
(unaudited)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents ..................... $ 36,241 $ 19,389
Short-term investments ........................ 11,112 17,428
Accounts receivable, net ...................... 11,623 7,954
Other current assets .......................... 2,466 706
--------- ---------
Total current assets ....................... 61,442 45,477
Property and equipment, net ....................... 18,261 12,285
Intangible assets, net ............................ 22,390 19,868
Other assets ...................................... 5,935 2,310
--------- ---------
$ 108,028 $ 79,940
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Notes payable ................................. $ 890 $ 1,213
Accounts payable .............................. 5,790 5,178
Accrued compensation .......................... 3,634 2,424
Accrued liabilities ........................... 9,946 4,559
Current portion of capital lease obligations .. 2,229 2,295
Deferred revenue .............................. 1,157 1,874
--------- ---------
Total current liabilities .................. 23,646 17,543
Capital lease obligations, net of current portion . 2,609 2,984
Stockholders' equity:
Convertible preferred stock, at amounts paid in -- 46,101
Common stock .................................. 7 5
Additional paid-in capital .................... 229,849 123,670
Deferred stock compensation ................... (8,521) (6,935)
Accumulated deficit ........................... (139,562) (103,428)
--------- ---------
Total stockholders' equity ................. 81,773 59,413
--------- ---------
$ 108,028 $ 79,940
========= =========
</TABLE>
See notes to condensed consolidated financial statements.
3
<PAGE> 4
HEALTHEON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data; unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
--------------------- ---------------------
1999 1998 1999 1998
-------- -------- -------- --------
<S> <C> <C> <C> <C> <C>
Revenue (1) ......................................... $ 22,698 $ 10,899 $ 40,253 $ 20,653
Operating costs and expenses:
Cost of operations (1) ........................... 17,914 9,348 33,432 16,846
Development and engineering ...................... 7,220 4,279 14,255 7,999
Sales, general and administrative ................ 10,886 6,915 19,787 11,631
Depreciation and amortization .................... 4,867 3,156 10,095 6,004
-------- -------- -------- --------
Total operating costs and expenses ............. 40,887 23,698 77,569 42,480
-------- -------- -------- --------
Loss from operations ................................ (18,189) (12,799) (37,316) (21,827)
Interest income ..................................... 739 279 1,436 637
Interest expense .................................... (115) (135) (254) (251)
Dividends on ActaMed's convertible
redeemable preferred stock ....................... -- -- -- (890)
-------- -------- -------- --------
Net loss ............................................ $(17,565) $(12,655) $(36,134) $(22,331)
======== ======== ======== ========
Basic and diluted net loss per common share ......... $ (0.25) $ (0.47) $ (0.55) $ (1.27)
======== ======== ======== ========
Weighted average shares outstanding used in computing
========
basic and diluted net loss per common share ...... 69,907 27,164 66,286 17,632
======== ======== ======== ========
</TABLE>
(1) Includes revenue to related parties of $10,751 and $4,714 and cost of
operations associated with revenue to related parties of $9,711 and $3,864
for the three months ended June 30, 1999 and 1998, and revenue related to
related parties of $20,272 and $9,370 and cost of operations associated
with revenue to related parties of $17,492 and $6,391 for the six months
ended June 30, 1999 and 1998. See note 3.
See notes to condensed consolidated financial statements.
4
<PAGE> 5
HEALTHEON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
<TABLE>
<CAPTION>
SIX MONTHS ENDED
JUNE 30,
-----------------------
1999 1998
-------- --------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss ........................................................ $(36,134) $(22,331)
Adjustments to reconcile net loss to net cash used in operating
activities:
Depreciation and amortization ................................. 14,996 9,235
Dividends on ActaMed's convertible redeemable preferred stock.. -- 890
Changes in operating assets and liabilities:
Accounts receivable ......................................... (3,669) (1,386)
Other assets ................................................ (6,252) 595
Accounts payable ............................................ 612 908
Accrued liabilities ......................................... 6,645 2,905
Deferred revenue ............................................ (717) 61
-------- --------
Net cash used in operating activities .................... (24,519) (9,123)
-------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of short-term investments ............................. (16,353) (3,483)
Maturities of short-term investments ............................ 22,669 7,057
Decrease in restricted cash ..................................... 867 --
Purchases of property and equipment ............................. (7,311) (2,664)
-------- --------
Net cash provided by (used in) investing activities ...... (128) 910
-------- --------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds (payments) on line of credit borrowings ................ (323) 48
Proceeds from issuance of preferred stock ....................... -- 2,034
Proceeds from issuance of common stock, net of issuance costs ... 43,245 913
Payments on note receivable from officer ........................ -- 349
Principal payments of capital lease obligations ................. (1,424) (560)
-------- --------
Net cash provided by financing activities ................ 41,498 2,784
-------- --------
Net increase (decrease) in cash and cash equivalents ................ 16,851 (5,429)
Cash and cash equivalents at beginning of period .................... 19,389 16,504
-------- --------
Cash and cash equivalents at end of period .......................... $ 36,240 $ 11,075
======== ========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid ................................................... $ 261 $ 269
======== ========
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Equipment acquired under capital leases ......................... $ 983 $ 1,604
======== ========
Issuance of common stock for assets purchased ................... $ 11,000 $ 4,900
======== ========
Issuance of convertible redeemable preferred stock for assets
purchased .................................................... $ -- $ 2,800
======== ========
Deferred compensation related to options granted ................ $ 6,261 $ 2,402
======== ========
Conversion of convertible preferred stock and convertible
redeemable preferred stock to common stock ................... $ 46,101 $ 94,119
======== ========
</TABLE>
See notes to condensed consolidated financial statements.
5
<PAGE> 6
HEALTHEON CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The unaudited condensed consolidated financial statements have been
prepared by Healtheon's management and reflect all adjustments that, in the
opinion of management, are necessary for a fair presentation of the interim
periods presented. The results of operations for the three and six months ended
June 30, 1999 are not necessarily indicative of the results to be expected for
any subsequent quarter or for the entire year ending December 31, 1999. Certain
information and footnote disclosures normally included in financial statements
prepared in accordance with generally accepted accounting principles have been
condensed or omitted under the Securities and Exchange Commission's rules and
regulations. A condensed consolidated statement of comprehensive loss has not
been presented because the components of comprehensive loss are not material.
Healtheon derives its revenue from a single operating segment, healthcare
transaction and information services delivered over the Internet, private
intranets or other networks and from development and consulting contracts
related to these services. In addition, we manage the information technology
operations of some of our customers. Healtheon's operations outside of the
United States are not significant, and to date we have derived nearly all of our
revenue from within the United States. Assets located outside of the United
States are insignificant at June 30, 1999.
These unaudited condensed consolidated financial statements and notes
included herein should be read in conjunction with Healtheon's audited
consolidated financial statements and notes for the year ended December 31, 1998
which were included in our Annual Report on Form 10-K filed with the Securities
and Exchange Commission.
Revenue Recognition
Healtheon earns revenue from services and services to related parties, both
of which include providing access to our network-based services and performing
development and consulting services, and from licensing software. Services
revenue also includes revenue from the management and operation of customers'
information technology, or IT, infrastructure. We earn network-based services
revenue from fixed fee subscription arrangements, which is recognized ratably
over the term of the applicable agreement, and from arrangements that are priced
on a per-transaction or per-user basis, which is recognized as the services are
performed. Revenue from development projects is recognized on a
percentage-of-completion basis or as such services are performed, depending on
the terms of the contract. Revenue from consulting services and revenue from the
management and operation of customers' IT infrastructure is recognized as the
services are performed. Cash received in excess of revenue recognized relating
to such services has been recorded as deferred revenue in the accompanying
condensed consolidated balance sheets. Revenue from services to related parties
consists of services revenue attributable to UnitedHealth Group and SmithKline
Labs. To date, we have derived no significant revenue from brokers, value-added
resellers or systems integrators.
During 1997, we entered into agreements with two customers to manage and
operate their current and expanding IT operations, to develop a suite of
specific Internet-based commercial software applications and to assist these
customers in migrating from their current IT operating environment to these new
applications. We utilize our own personnel, certain outside contractors and
certain personnel and facilities of the customers that are leased under contract
terms to use for these services. The cost of these leased customer personnel and
facilities is included as a part of the total costs of the IT and development
services that we bill to the customers. We recognized revenue for the IT
services of approximately $4,352,000 and $3,505,000 in the three months ended
June 30, 1999 and 1998, and $9,279,000 and $7,304,000 in the six months ended
June 30, 1999 and 1998. We recognized revenue for the development services of
approximately $2,724,000 and $1,720,000 in the three months ended June 30, 1999
and 1998, and $3,273,000 and $2,497,000 in the six months ended June 30, 1999
and 1998. Revenue recognized for IT services included $2,856,000 and $6,321,000
in the three and six months ended June 30, 1999 and $2,638,000 and $6,088,000 in
the three and six months ended June 30, 1998, related to leased personnel and
facilities. These amounts were also included in cost of operations for the
respective periods.
We recognize revenue from license fees when a noncancellable license
agreement has been signed with a customer, the software product covered by the
license agreement has been delivered, there are no uncertainties
6
<PAGE> 7
surrounding product acceptance, there are no significant future performance
obligations, the license fees are fixed and determinable and collection of the
license fees is considered probable. Our products do not require significant
customization.
Concentration of Credit Risk
Healtheon currently derives a substantial portion of its consolidated
revenue from a few large customers, two of which are related parties (see Note
3). We believe that the concentration of credit risk in our trade receivables,
with respect to our limited customer base, is substantially mitigated by our
credit evaluation process. We do not require collateral. To date, our bad-debt
write-offs have not been significant.
Net Loss per Common Share
The following table presents the calculation of basic and diluted net loss
per common share (in thousands, except per share data):
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
--------------------- ---------------------
1999 1998 1999 1998
-------- -------- -------- --------
<S> <C> <C> <C> <C>
Net loss .......................................... $(17,565) $(12,655) $(36,134) $(22,331)
======== ======== ======== ========
Basic and diluted:
Weighted-average shares of common stock
outstanding .................................. 70,935 28,500 67,362 18,999
Less: Weighted-average common shares subject to
repurchase ................................... (1,028) (1,336) (1,076) (1,367)
-------- -------- -------- --------
Weighted-average shares used in computing basic and
diluted net loss per common share .............. 69,907 27,164 66,286 17,632
======== ======== ======== ========
Basic and diluted net loss per common share ....... $ (0.25) $ (0.47) $ (0.55) $ (1.27)
======== ======== ======== ========
</TABLE>
We have excluded all convertible redeemable preferred stock, convertible
preferred stock, warrants, outstanding stock options and shares subject to
repurchase by Healtheon from the calculation of diluted net loss per common
share because all such securities are anti-dilutive for the periods presented.
The total number of shares excluded from the calculations of diluted loss per
share was approximately 18,060,000 at June 30, 1999 and 12,379,000 at June 30,
1998.
Reclassifications
Certain reclassifications have been made to the financial statements to
conform with the current year's presentation.
2. SERVICES AGREEMENT WITH SMITHKLINE BEECHAM CLINICAL LABORATORIES, INC.
In January 1999, Healtheon and SmithKline Beecham Clinical Laboratories,
Inc., or SmithKline Labs, entered into a services agreement under which
Healtheon will provide certain electronic laboratory results delivery services
7
<PAGE> 8
to approximately 20,000 provider sites, in addition to the sites currently
served through the SCAN service. In addition, in January 1999, the two companies
completed an asset purchase agreement under which Healtheon purchased certain
assets currently used by SmithKline Labs to provide these laboratory results
delivery services in exchange for $2,000,000 in cash and 1,833,333 shares of
Healtheon's common stock with a value of $11,000,000. Of the total purchase
price, $9,137,000 was allocated to intangible assets in the accompanying
condensed consolidated balance sheet, which are being amortized over five years.
3. RELATED PARTY TRANSACTIONS
Revenue from services to related parties consists of revenue attributable
to two customers who are significant stockholders of Healtheon. Receivables due
from these related parties included in accounts receivable on the condensed
consolidated balance sheets were approximately $4,472,000 at June 30, 1999 and
$3,360,000 at December 31, 1998.
4. STOCKHOLDERS' EQUITY
From January 1, 1999 through February 10, 1999, the date of our initial
public offering, Healtheon granted to employees options to purchase common stock
and issued shares of common stock under restricted stock purchase agreements
equal to a total of 4,107,625 shares of common stock at exercise or purchase
prices ranging from $3.55 to $5.85 per share. During 1999, we have recorded
additional deferred stock compensation of $6,261,000 with regard to these
grants.
On February 10, 1999, Healtheon completed its initial public offering. We
sold 5,750,000 shares of common stock to the public and realized net proceeds of
approximately $41,398,000.
5. PROPOSED MERGERS
On April 21, 1999 we announced that we have entered into an agreement to
acquire MEDE America Corporation ("MEDE AMERICA"), a leading provider of
healthcare transaction solutions for pharmacies, hospitals, physicians,
dentists, payers and pharmacy benefits managers (PBMs). Under the terms of the
agreement, Healtheon will exchange 0.6593 shares of common stock, subject to
adjustment if the price of the Healtheon stock is less than $38.39 as determined
by a formula just prior to closing, for each share of MEDE AMERICA stock. The
transaction is preliminarily valued at approximately $525.3 million. The
acquisition, which will be accounted for using the purchase method of
accounting, is anticipated to be completed in late third quarter or early fourth
quarter of 1999. The transaction is subject to customary closing conditions,
including approval by MEDE AMERICA stockholders, and is subject to regulatory
review.
On May 20, 1999, we announced that we have entered into an agreement to
merge with WebMD, Inc. ("WebMD"), a leading provider of integrated Web-based
solutions for the administrative, communications and information needs of
healthcare professionals and the healthcare information needs of consumers.
Under the terms of the agreement, Healtheon will exchange 1.815 shares of common
stock for each share of WebMD stock. The transaction is preliminarily valued at
approximately $6,671.6 million. The merger, which will be accounted for using
the purchase method of accounting, is anticipated to be completed in late third
quarter or early fourth quarter of 1999. The transaction is subject to customary
closing conditions, including approval by WebMD and Healtheon stockholders, and
is subject to regulatory review.
On June 30, 1999, we entered into an agreement to acquire Greenberg News
Networks, Inc., owners of Medcast Networks ("Medcast"), a leading Internet-based
medical news and information service. Pursuant to the Agreement and Plan of
Merger, we will enter into a strategic business combination with Medcast,
conditioned upon and concurrent with the closing of our previously agreed to
merger with WebMD. Under the terms of the agreement, Healtheon/WebMD Corporation
will exchange 0.5483 shares of common stock for each share of Medcast stock. The
transaction is preliminarily valued at approximately $215.0 million. The
acquisition, which will be accounted for using the purchase method of
accounting, is anticipated to be completed in late third quarter or early fourth
quarter of 1999. The transaction is subject to customary closing conditions,
including approval by Medcast stockholders, and is subject to regulatory review.
8
<PAGE> 9
- --------------------------------------------------------------------------------
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
- --------------------------------------------------------------------------------
FORWARD LOOKING STATEMENTS
Except for historical information, this Report contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These forward-looking
statements involve risks and uncertainties, including, among other things,
statements regarding our anticipated costs and expenses, revenue mix, product
and service development, relationships with strategic partners and plans for
addressing Year 2000 issues. These forward-looking statements include, among
others, those statements including the words "expects," "anticipates,"
"intends," "believes" and similar language. Our actual results may differ
materially from those projected in the forward-looking statements. Factors that
might cause or contribute to such differences include, but are not limited to,
those discussed in the section "--Factors That May Affect Future Results of
Operations." You should carefully review the risks described in other documents
we file from time to time with the Securities and Exchange Commission, including
our Annual Report on Form 10-K for the year ended December 31, 1998 and the
Registration Statement on Form S-4 filed by Healtheon/WebMD Corporation on June
16, 1999, as amended. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this Quarterly
Report on Form 10-Q. We undertake no obligation to publicly release any
revisions to the forward-looking statements or reflect events or circumstances
after the date of this document.
The following discussion also should be read in conjunction with the
consolidated financial statements and notes thereto for the year ended December
31, 1998 included in our Annual Report on Form 10-K as filed with the Securities
and Exchange Commission.
OVERVIEW
Healtheon is pioneering the use of the Internet to simplify workflows,
decrease costs and improve the quality of patient care throughout the healthcare
industry. Healtheon's Virtual Healthcare Network, or VHN, solution enables the
secure exchange of information among a wide array of disparate healthcare
information systems and provides a framework for a broad range of healthcare
transactions.
Because Healtheon has recently begun operations, it is difficult to
evaluate our business and prospects. Our revenue and income potential is
unproven and our business model is still emerging. Our historical financial
information is of limited value in projecting our future operating results
because of our limited operating history as a combined organization and the
emerging nature of our markets. We have lost money since we began operations
and, as of June 30, 1999, we had an accumulated deficit of $139.6 million. We
plan to invest heavily in acquisitions, infrastructure development, applications
development and sales and marketing. As a result, we expect that we will
continue to lose money through 1999 and we may never achieve or sustain
profitability.
On April 21, 1999 we announced that we have entered into an agreement to
acquire MEDE America Corporation ("MEDE AMERICA"), a leading provider of
healthcare transaction solutions for pharmacies, hospitals, physicians,
dentists, payers and pharmacy benefits managers (PBMs). Under the terms of the
agreement, Healtheon will exchange 0.6593 shares of common stock, subject to
adjustment if the price of the Healtheon stock is less than $38.39 as determined
by a formula just prior to closing, for each share of MEDE AMERICA stock. The
transaction is preliminarily valued at approximately $525.3 million. The
acquisition, which will be accounted for using the purchase method of
accounting, is anticipated to be completed in late third quarter or early fourth
quarter of 1999. The transaction is subject to customary closing conditions,
including approval by MEDE AMERICA stockholders, and is subject to regulatory
review.
On May 20, 1999, we announced that we have entered into an agreement to
merge with WebMD, Inc. ("WebMD"), a leading provider of integrated Web-based
solutions for the administrative, communications and information needs of
healthcare professionals and the healthcare information needs of consumers.
Under the terms of the agreement, Healtheon will exchange 1.815 shares of common
stock for each share of WebMD stock. The transaction is preliminarily valued at
approximately $6,671.6 million. The merger, which will be accounted for using
the purchase method of accounting, is anticipated to be completed in late third
quarter or early fourth quarter of 1999. The transaction is subject to customary
closing conditions, including approval by WebMD and Healtheon stockholders, and
is subject to regulatory review.
9
<PAGE> 10
On June 30, 1999, we entered into an agreement to acquire Greenberg News
Networks, Inc., owners of Medcast Networks ("Medcast"), a leading Internet-based
medical news and information service. Pursuant to the Agreement and Plan of
Merger, we will enter into a strategic business combination with Medcast,
conditioned upon and concurrent with the closing of our previously agreed to
merger with WebMD. Under the terms of the agreement, Healtheon/WebMD Corporation
will exchange 0.5483 shares of common stock for each share of Medcast stock. The
transaction is preliminarily valued at approximately $215.0 million. The
acquisition, which will be accounted for using the purchase method of
accounting, is anticipated to be completed in late third quarter or early fourth
quarter of 1999. The transaction is subject to customary closing conditions,
including approval by Medcast stockholders, and is subject to regulatory review.
If the above transactions are consummated, the purchase price of these
transactions will be amortized over the useful lives of the tangible and
intangible assets. We currently anticipate that this amortization will cause us
to incur significant net losses for the next several years, and expect to incur
increasing net operating losses and negative cash flows for the foreseeable
future and may never reach profitability.
RESULTS OF OPERATIONS
Revenue
We have developed strategic relationships with healthcare industry leaders,
including UnitedHealth Group, SmithKline Labs, Brown & Toland and Beech Street.
These four companies each accounted for over 10% of our total revenue in the six
months ended June 30, 1999. We expect that a small number of customers will
continue to account for a substantial portion of our revenue for the foreseeable
future. The loss of one or more of our significant customers, or a decline in
the volume of business generated by these customers, could have a material
adverse effect on our business, financial condition and results of operations.
Healtheon earns revenue from services that include providing access to our
network-based services, including fixed fee and transaction based services, and
performing development and consulting services, including the management and
operation of customers' IT infrastructure, and from licensing software.
Customers may purchase some or all of Healtheon's applications and services and
the customer relationship may evolve from utilizing development and consulting
services to utilizing transaction and subscription-based services. Healtheon
earns network-based services revenue from fixed fee subscription arrangements,
which revenue is recognized ratably over the term of the applicable agreement,
and from arrangements that are priced on a per-transaction or per-user basis,
which revenue is recognized as the services are performed. Revenue from
development projects is recognized on a percentage-of-completion basis or as the
services are performed, depending on the terms of the contract. Revenue from
consulting services and revenue from the management and operation of customers'
IT infrastructure is recognized as the services are performed. Cash received in
excess of revenue recognized relating to these services has been recorded as
deferred revenue. At June 30, 1999, we had deferred revenue of approximately
$1.2 million.
Total revenue increased to $22.7 million and $40.3 million in the three and
six months ended June 30, 1999 from $10.9 million and $20.7 million in the three
and six months ended June 30, 1998. Revenue from the service agreements with
UnitedHealth and SmithKline Labs increased to $10.8 million and $20.3 million in
the three and six months ended June 30, 1999, compared to $4.7 million and $9.4
million in the three and six months ended June 30, 1998. Increased
transaction-based services under the UnitedHealth Group agreement, and
additional revenue from the January 1999 services agreement with SmithKline
Labs, which was phased in during the first quarter of 1999, contributed to the
significant increases in revenue.
The UnitedHealth Group agreement has a five-year term. However, the
agreement provides that two years after the date of the agreement, which was
signed on April 4, 1996, the parties will agree on new prices that are
competitive with the marketplace. Healtheon and UnitedHealth Group are
negotiating the new prices and we anticipate that the new prices will reduce the
rates paid by UnitedHealth Group on a prospective basis. The services agreements
with SmithKline Labs also each have a five-year term. However, the December 1997
services agreement provides that the parties will negotiate new rates as of
January 1, 2001 and every two years thereafter. Under the terms of this services
agreement, the renegotiated rates must be competitive with the marketplace and
must be no higher than the lowest fees charged by Healtheon to similar
customers.
10
<PAGE> 11
In December 1996, through a subsidiary, Healtheon entered into an
agreement to license its newly granted patent to International Business Machines
Corporation ("IBM"). IBM agreed to pay $4.8 million over a four-year period,
$1.0 million in December 1996 and the remaining balance in 48 equal monthly
installments commencing in January 1997. Additionally, we issued IBM a five-year
warrant to purchase 282,522 shares of our common stock at a price of $7.97 per
share. Because of the extended payment terms and the subsidiary's contentious
relationship with IBM, we concluded that collection was not assured and,
accordingly, we were recognizing this revenue as the proceeds were collected. In
January 1999, we announced an enhanced relationship with IBM, where both parties
agreed to jointly market and sell each company's products to their healthcare
customers. Since then, we have been in further discussions with IBM on
additional strategic opportunities, and as a part of these discussions, in June,
1999 we amended the agreement with IBM such that the remaining payment stream
was discounted in exchange for immediate payment of the revised balance due,
resulting in the recognition of the remaining deferred revenue. As a result, we
recognized revenue of $1.3 million and $1.5 million in the three and six months
ended June 30, 1999 and $0.2 million and $0.4 million in the three and six
months ended June 30, 1998. We do not currently anticipate that we will earn a
material amount of revenue from software licenses in the foreseeable future.
Cost of Operations
Cost of operations consists of costs related to services Healtheon
provides to customers and costs associated with the operation and maintenance of
our networks. These costs include salaries and related expenses for consulting
and development personnel, network operations personnel and customer support
personnel; telecommunication costs; maintenance of network equipment; a portion
of facilities expenses; and leased personnel and facilities costs. Given
Healtheon's limited operating history, changes in revenue mix, limited history
of Internet-based network services, recent investments in personnel,
amortization of infrastructure investments and evolving business model, we
believe that analysis of historical cost of operations as a percentage of
revenue is not meaningful. We anticipate that our total cost of operations will
increase in absolute dollars in the future.
Cost of operations increased to $17.9 million and $33.4 million in the
three and six months ended June 30, 1999 from $9.3 million and $16.8 million in
the three and six months ended June 30, 1998. These increases resulted mainly
from higher personnel and network operations costs required to support the
increased revenues.
Development and Engineering
Development and engineering expense, which excludes development expenses
that are included in cost of operation, consists primarily of salaries and
related expenses associated with the development of applications and services.
Expenses include compensation paid to engineering personnel, fees to outside
contractors and consultants, a portion of facilities expenses and the
maintenance of capital equipment used in the development process. We believe our
success is partially dependent upon our ability to introduce new applications in
several healthcare markets in a relatively short period of time. Accordingly,
Healtheon intends to continue recruiting and hiring experienced engineering
personnel and to continue making other investments in development and
engineering. We expect that development and engineering expenses will continue
to increase in absolute dollars. Currently, all development and engineering
expenses are expensed as incurred.
Development and engineering expense was $7.2 million and $14.3 million in
the three and six months ended June 30, 1999 and $4.3 million and $8.0 million
in the three and six months ended June 30, 1998. The increases were the result
of a significant increase in the number of engineers engaged in the development
of our applications and services.
Sales, General and Administrative
Sales, general and administrative expense consists primarily of salaries
and related expenses for sales, account management, marketing, administrative,
finance, legal, human resources and executive personnel; commissions; costs and
expenses for marketing programs and trade shows; fees for professional services;
and costs of accounting and internal control systems to support our operations.
We anticipate that sales, general and administrative expenses will continue to
increase in absolute dollars as we add sales, marketing and administrative
personnel, increase our
11
<PAGE> 12
marketing and promotional activities and incur costs related to being a public
company, such as directors' and officers' liability insurance premiums and
professional fees.
Sales, general and administrative expense increased to $10.9 million and
$19.8 million in the three and six months ended June 30, 1999 from $6.9 million
and $11.6 million in the three and six months ended June 30, 1998. The
amortization of deferred stock compensation expense was $2.1 million and $4.2
million in the three and six months ended June 30, 1999, compared to $0.7
million and $1.1 million in the comparable periods of the prior year.
Substantially all of the remainder of the increase resulted from salaries and
related support costs for added sales and administrative personnel and executive
management.
Deferred stock compensation represents the difference between the purchase
or exercise price of certain restricted stock and stock option grants and the
deemed fair value of Healtheon's common stock at the time of those grants.
Healtheon recorded deferred stock compensation of $6.3 million in the first six
months of 1999, $8.2 million in the full year of 1998 and $2.7 million in the
full year of 1997. The unamortized deferred stock compensation balance at June
30, 1999 was $8.5 million. The deferred stock compensation balance is being
amortized based on a graded vesting method over the vesting period, generally
four years, of the option or restricted stock grants. Amortization is estimated
to total $3.4 million during the remainder of 1999, $3.3 million in 2000, $1.4
million in 2001 and $0.4 million for 2002.
Depreciation and Amortization
Depreciation expense and amortization of intangible assets was $4.9 million
and $10.1 million in the three and six months ended June 30, 1999 and $3.2
million and $6.0 million in the three and six months ended June 30, 1998.
Property and equipment is being depreciated over the estimated useful lives of
the related assets, generally three to seven years. All of the intangible assets
are being amortized over an expected lives of two to five years. The increases
resulted primarily from the January 1999 Services Agreement with SmithKline Labs
and the acquisition of Metis LLC in August 1998. Amortization charges are
estimated to be $11.8 million in 1999, $10.0 million in 2000, $3.4 million in
2001, $1.8 million in both 2002 and 2003 and $.2 million in 2004 assuming no
impairment of the remaining unamortized intangible asset balances and no
additional acquisitions of intangible assets.
Interest Income and Expense
Interest income has been derived primarily from the investment of excess
cash. Interest expense results primarily from our borrowings and from
capitalized lease obligations for equipment purchases. Interest income was $1.4
million in the first six months of 1999 and $0.6 million in the first six months
of 1998. The increase for the 1999 period was due to higher average cash
balances resulting from the proceeds of our $46.1 million preferred stock
financing in October 1998 and the net proceeds of $41.4 million from our initial
public offering in February 1999.
Dividends on ActaMed's Convertible Redeemable Preferred Stock
Healtheon acquired ActaMed in a transaction accounted for as a
pooling-of-interests in May 1998. Because dividends on ActaMed's convertible
redeemable preferred stock were cumulative whether declared or not, ActaMed
accrued the dividends on a quarterly basis. Dividends of $.9 million were
charged against income in the consolidated statements of operations in both the
three and six months ended June 30, 1998. None of the dividends were paid, and,
in conjunction with approving the acquisition of ActaMed by Healtheon, ActaMed's
preferred stockholders waived their right to receive the dividends, which
totaled $7.5 million at the time of the acquisition. The ActaMed preferred
stockholders received an aggregate of 17,252,408 shares of Healtheon common
stock in exchange for their ActaMed convertible redeemable preferred stock.
12
<PAGE> 13
FACTORS THAT MAY AFFECT FUTURE RESULTS OF OPERATIONS
Healtheon/WebMD Corporation has filed a registration statement on Form S-4
with the Securities and Exchange Commission relating to proposed acquisitions of
Healtheon, WebMD, Inc., MeDE AMERICA and Greenberg News Networks, Inc. We will
face additional risks to our business as a result of these acquisitions. We
encourage you to carefully read the registration statement, including risks
identified under the caption "Risk Factors," for a more thorough discussion of
the acquisition and the risks facing the combined company.
OUR QUARTERLY OPERATING RESULTS MAY VARY, WHICH COULD AFFECT THE MARKET PRICE
OF OUR COMMON STOCK.
Fluctuations in our quarterly results could affect the market price of our
common stock in a manner unrelated to our long-term operating performance. We
expect that our quarterly revenue and operating results may fluctuate as a
result of a number of factors discussed throughout this risk factor section.
We expect to increase activities and spending in substantially all of our
operational areas. We base our expense levels in part upon our expectations
concerning future revenue and these expense levels are relatively fixed in the
short-term. If we have lower revenue, we may not be able to reduce our spending
in the short-term in response. Any shortfall in revenue would have a direct
impact on our results of operations. For these and other reasons, we may not
meet the earnings estimates of securities analysts or investors and our stock
price could suffer.
THE HEALTHCARE INDUSTRY MAY NOT ACCEPT OUR SOLUTIONS.
We must attract a significant number of customers throughout the healthcare
industry. To date, the healthcare industry has been resistant to adopting new
information technology solutions and these healthcare participants may not adopt
our solutions. Electronic information exchange and transaction processing by the
healthcare industry is still developing. We believe that complexities in the
nature of the healthcare transactions that must be processed have hindered the
development and acceptance of information technology solutions by the industry.
Conversion from traditional methods to electronic information exchange may not
occur as rapidly as we expect it will. Even if the conversion does occur as
rapidly as we expect, healthcare industry participants may use applications and
services offered by others.
We believe that we must gain significant market share with our applications
and services before our competitors introduce alternative products, applications
or services with features similar to our current or proposed offerings. Our
business plan is based on our belief that the value and market appeal of our
solution will grow as the number of participants and the scope of the
transaction services available on our platform increase. We may not achieve the
critical mass of users we believe is necessary. In addition, we expect to
generate a significant portion of our revenue from subscription and
transaction-based fees. Consequently, any significant shortfall in the number of
users or transactions occurring over our platform would adversely affect our
revenue.
WE RELY ON STRATEGIC RELATIONSHIPS TO GENERATE REVENUE.
We must establish and maintain strategic relationships with leaders in a
number of healthcare industry segments. This is critical to us because we
believe that these relationships will enable us to:
o extend the reach of our applications and services to the various
participants in the healthcare industry;
o obtain specialized healthcare expertise;
o develop and deploy new applications;
o further enhance the Healtheon brand; and
o generate revenue.
We may not be able to establish commercial acceptance of our platform
applications and services if we lose any of our strategic relationships, fail to
obtain modifications of exiting relationships, or fail to establish additional
relationships, or if our strategic partners fail to actively pursue additional
business relationships and partnerships with us.
Entering into strategic relationships is complicated because some of our
current and future partners may decide to compete with us. In addition, we may
not be able to maintain or establish relationships with key participants in the
healthcare industry if we have established relationships with competitors of
these key participants. Consequently, it is important that we are perceived as
independent of any particular customer or partner. Moreover, many potential
partners may resist working with us until our applications and services have
been successfully introduced and have achieved market acceptance.
As we establish strategic relationships, we will depend on our partners'
ability to generate increased acceptance and use of our platform, applications
and services. To date, we have established only a limited number of strategic
relationships and these relationships are in the early stages of development. We
have limited experience in
13
<PAGE> 14
establishing and maintaining strategic relationships with healthcare industry
participants. If we lose any of these strategic relationships or fail to
establish additional relationships, or if our strategic partners fail to
actively pursue additional business relationships and partnerships, we would not
be able to execute our business plans and our business would suffer
significantly.
OUR ABILITY TO GENERATE REVENUE WILL SUFFER IF WE DO NOT QUICKLY EXPAND OUR
SUITE OF APPLICATIONS.
We currently offer a limited number of applications on our platform and our
future success depends on quickly introducing new applications in several
healthcare segments. We do not have the internal resources and specialized
healthcare expertise to develop all these applications independently.
Consequently, we must rely on a combination of internal development, strategic
relationships, licensing and acquisitions to develop these applications. Each of
our applications, regardless of how it was developed, must be integrated and
customized to operate with existing customer legacy computer systems and our
platform. Developing, integrating and customizing these applications will be
expensive and time consuming, and these applications may never achieve market
acceptance, which could also cause our business to suffer.
WE MUST ACQUIRE TECHNOLOGIES AND COMPANIES TO INCREASE OUR CUSTOMER BASE.
We expect to continue to acquire technologies and other healthcare
technology companies to increase the number and variety of applications on our
platform and to increase our customer base. For example, in May 1998 we acquired
ActaMed, in August 1998 we acquired substantially all the assets of Metis, LLC,
in April 1999 we announced that we have entered into an agreement to acquire
MEDE America Corporation, in May 1999 we announced that we have entered into an
agreement to merge with WebMD, Inc., and in June 1999 we entered into an
agreement to acquire Greenberg News Networks, Inc., owners of Medcast Networks.
See notes 5 of notes to condensed consolidated financial statements. To be
successful, we will need to identify applications, technologies and businesses
that are complementary to ours, integrate disparate technologies and corporate
cultures and manage a geographically dispersed company. Acquisitions could
divert our attention from other business concerns and expose us to unforeseen
liabilities or risks associated with entering new markets. Finally, we may lose
key employees while integrating these new companies.
Integrating newly acquired organizations and technologies into our company
could be expensive, time consuming and may strain our resources. In addition, we
may lose our current customers if any acquired companies have relationships with
competitors of our customers. Consequently, we may not be successful in
integrating acquired businesses or technologies and may not achieve anticipated
revenue and cost benefits. The healthcare industry is consolidating and we
expect that we will face intensified competition for acquisitions, especially
from larger, better-funded organizations. If we fail to execute our acquisition
strategy successfully for any reason, our business will suffer significantly.
We intend to pay for some of our acquisitions by issuing additional common
stock and this could dilute our stockholders. We may also use cash to buy
companies or technologies in the future. If we do use cash, we may need to incur
debt to pay for these acquisitions. Acquisition financing may not be available
on favorable terms or at all. In addition, we may be required to amortize
significant amounts of goodwill and other intangible assets in connection with
our contemplated and future acquisitions, which would materially increase our
operating expenses.
WE MAY LOSE CONTRACTUAL RIGHTS WITH SUPPLIERS, CUSTOMERS AND OTHER BUSINESS
PARTNERS DUE TO THE PROPOSED ACQUISITIONS.
Healtheon, WebMD, MEDE AMERICA and Medcast have contracts with many
sponsors, customers and other business partners. Some of these contracts require
Healtheon, WebMD, MEDE AMERICA and Medcast to obtain the consent, waiver or
approval of these other parties in connection with the proposed reorganizations.
If consent, waiver or approval cannot be obtained, we may lose the right to use
intellectual property or other rights that are necessary for smooth operations.
Healtheon, WebMD, MEDE AMERICA and Medcast have agreed to seek to secure the
necessary consents, waivers and approvals. However, Healtheon, WebMD, MEDE
AMERICA and Medcast may not be able to obtain all of the necessary consents,
waivers and approvals.
In addition, Healtheon, WebMD, MEDE AMERICA and Medcast each have granted
exclusive rights to third parties with regard to certain content, sponsorship or
other strategic relationships. Some of these rights conflict with
14
<PAGE> 15
rights granted by the other parties. We may not successfully resolve these
conflicts and failure to do so could harm our business.
WE WILL FACE TECHNICAL, OPERATIONAL AND STRATEGIC CHALLENGES THAT MAY PREVENT
US FROM SUCCESSFULLY INTEGRATING HEALTHEON, WEBMD, MEDE AMERICA AND MEDCAST.
The proposed transactions with WebMD, MEDE AMERICA and Medcast, and
resulting reorganizations, involve risks related to the integration and
management of acquired technology, operations and personnel. The integration of
Healtheon, WebMD, MEDE AMERICA and Medcast will be a complex, time consuming and
expensive process and may disrupt our business if not completed in a timely and
efficient manner. Following the reorganizations, we must operate as a combined
organization utilizing common information and communication systems, operating
procedures, financial controls and human resources practices. We may encounter
substantial difficulties, costs and delays involved in the proposed
integrations, including:
o potential incompatibility of business cultures;
o perceived adverse changes in business focus;
o potential conflicts in sponsor, advertising or content relationships;
and
o diversion of the attention of management from other ongoing business
concerns.
OUR BUSINESS WILL SUFFER IF WE FAIL TO MANAGE OUR GROWTH.
We have rapidly and significantly expanded our operations and expect to
continue to do so. This growth has placed, and is expected to continue to place,
a significant strain on our managerial, operational, financial and other
resources. As of June 30, 1999, we have grown to 824 employees and independent
contractors, from 648 employees and independent contractors on December 31,
1998, and from 176 employees and independent contractors on December 31, 1997. A
large portion of this increase resulted from our acquisitions of ActaMed in May
1998 and Metis, LLC in August 1998, which increased our payroll by 230
employees. We expect to continue to hire a significant number of new employees
to support our business. In addition, the proposed transactions with WebMD, MedE
AMERICA and Medcast will increase our headcount significantly.
Our current information systems, procedures and controls may not continue
to support our operations and may hinder our ability to exploit the market for
healthcare applications and services. We are in the process of evaluating our
accounting and management information systems and anticipate that we may
implement new systems within the next twelve months. We could experience
interruptions to our business while we transition to new systems.
OUR BUSINESS WILL SUFFER IF COMMERCIAL USERS DO NOT ACCEPT INTERNET
SOLUTIONS.
Our business model depends on the adoption of Internet solutions by
commercial users. Our ability to generate revenues could suffer dramatically if
Internet solutions are not accepted or not perceived to be effective. The
Internet may not prove to be a viable commercial marketplace for a number of
reasons, including:
o inadequate development of the necessary infrastructure for communication
speed, access and server reliability;
o security and confidentiality concerns relating to conducting
transactions over the Internet;
o lack of development of complementary products, such as high-speed modems
and high-speed communication lines; and
o delays in the development or adoption of new standards and protocols
required to handle increased levels of Internet activity.
The internet infrastructure may be unable to support the demands placed on
it by this continued growth. The adoption of Internet solutions by healthcare
participants will require the acceptance of a new way of conducting business and
exchanging information. The healthcare industry, in particular, relies on legacy
systems that may be unable to benefit from our Internet-based platform. To
maximize the benefits of our platform, healthcare participants must be willing
to allow sensitive information to be stored in our databases. We can process
transactions for healthcare participants that maintain information on their own
proprietary databases. However, the benefits of our connectivity and
sophisticated information management solution are limited under these
circumstances. Customers using legacy and
15
<PAGE> 16
client-server systems may refuse to adopt new systems when they have made
extensive investment in hardware, software and training for older systems.
PERFORMANCE PROBLEMS WITH OUR SYSTEMS COULD DAMAGE OUR BUSINESS.
Our customer satisfaction and our business could be harmed if we or our
customers experience any system delays, failures or loss of data. We currently
process substantially all of our customer transactions and data at our
facilities in Santa Clara, California and Atlanta, Georgia. Although we have
safeguards for emergencies, we do not have backup facilities to process
information if either of these facilities is not functioning. The occurrence of
a major catastrophic event or other system failure at either the Santa Clara or
the Atlanta facility could interrupt data processing or result in the loss of
stored data. In addition, we depend on the efficient operation of Internet
connections from customers to our systems. These connections, in turn, depend on
the efficient operation of Web browsers, Internet service providers and Internet
backbone service providers, all of which have had periodic operational problems
or experienced outages.
We depend on service and content providers to provide information and data
feeds on a timely basis. Our web site could experience distributions or
interruptions in service due to the failure or delay in the transmission or
receipt of this information. In addition, our customers depend on Internet
service providers, online service providers and other web site operators for
access to our web site. All of these providers have experienced significant
outages in the past and could experience outages, delays and other difficulties
in the future due to system failures unrelated to our systems. Any significant
interruptions in our services or increases in response time could result in a
loss of potential or existing customers, strategic partners, advertisers or
sponsors and, if sustained or repeated, could reduce the attractiveness of our
services.
Many of our service agreements contain performance standards. If we fail to
meet these standards, our customers could terminate their agreements with us.
The loss of any of our service agreements would directly and significantly
impact our business. We may be unable to expand or adapt our network
infrastructure to meet additional demand or our customers' changing needs on a
timely basis and at a commercially reasonable cost, or at all.
IF OUR SYSTEMS EXPERIENCE SECURITY BREACHES OR ARE OTHERWISE PERCEIVED TO BE
INSECURE, OUR REPUTATION WILL SUFFER.
A material security breach could damage our reputation or result in
liability to us. We retain confidential customer and patient information in our
processing centers. We may be required to spend significant capital and other
resources to protect against security breaches or to alleviate problems caused
by breaches. Any well-publicized compromise of Internet security could deter
people from using the Internet or from conducting transactions that involve
transmitting confidential information, including confidential healthcare
information. Therefore, it is critical that our facilities and infrastructure
remain secure and that our facilities and infrastructure are perceived by the
marketplace to be secure. Despite the implementation of security measures, our
infrastructure may be vulnerable to physical break-ins, computer viruses,
programming errors, attacks by third parties or similar disruptive problems.
TECHNOLOGY MAY CHANGE FASTER THAN WE CAN UPDATE OUR APPLICATIONS AND
SERVICES.
Healthcare information exchange and transaction processing is a relatively
new and evolving market. The pace of change in our markets is rapid and there
are frequent new product introductions and evolving industry standards. We may
be unsuccessful in responding to technological developments and changing
customer needs. In addition, our applications and services offerings may become
obsolete due to the adoption of new technologies or standards.
OUR PLATFORM INFRASTRUCTURE AND ITS SCALABILITY ARE NOT PROVEN AND IT MAY
FAIL TO RESPOND TO NEW GROWTH.
So far, we have processed a limited number and variety of transactions over
our platform. Similarly, a limited number of healthcare participants use our
platform. Our systems may not accommodate increased use while maintaining
acceptable overall performance. We must continue to expand and adapt our network
infrastructure to accommodate additional users, increased transaction volumes
and changing customer requirements. This expansion and adaptation will be
expensive and will divert our attention from other activities.
OUR REVENUES ARE CONCENTRATED IN A FEW CUSTOMERS, AND OUR ABILITY TO GENERATE
REVENUE WOULD SUFFER IF WE LOST ANY OF THESE CUSTOMERS.
16
<PAGE> 17
We expect that we will generate a significant portion of our revenue from a
small number of customers for the next few years. If we do not generate as much
revenue from these customers as we expect, or if we lose any of these customers,
our revenue will be significantly reduced which would harm our business. For
example, we receive a substantial majority of our revenue from four customers.
UnitedHealth Group, SmithKline Labs, Brown & Toland and Beech Street each
accounted for over 10% and together accounted for approximately 82% of our total
revenue in the first six months of 1999. In addition, these four customers each
accounted for over 10% and together accounted for approximately 87% of our total
revenue in the full year of 1998. As of June 30, 1999, UnitedHealth Group owned
approximately 12.7% of our stock and SmithKline Labs owned approximately 8.8% of
our stock.
WE FACE SIGNIFICANT COMPETITION.
The market for healthcare information services is intensely competitive,
rapidly evolving and subject to rapid technological change. Many of our
competitors have greater financial, technical, product development, marketing
and other resources than we have. These organizations may be better known and
have more customers than us. We may be unable to compete successfully against
these organizations.
Many of our competitors have announced or introduced Internet strategies
that will compete with our applications and services. We have many competitors,
including:
o healthcare information software vendors, including McKesson HBOC and
Shared Medical Systems Corporation;
o healthcare electronic data interchange companies, including ENVOY
Corporation and National Data Corporation;
o large information technology consulting service providers, including
Andersen Consulting, International Business Machines Corporation and
Electronic Data Systems Corporation; and
o small regional organizations.
In addition, we expect that major software information systems companies
and others specializing in the healthcare industry will offer competitive
applications or services. Some of our large customers may also compete with us.
We will also compete for subscribers, consumers, content and service providers,
advertisers, sponsors and acquisition candidates with the following categories
of companies:
o online services or web sites targeted to the healthcare industry and
healthcare consumers generally, including medscape.com, pol.net,
ivillage.com, medcareonline.com, mediconsult.com, betterhealth.com,
drkoop.com, onhealth.com, healthcentral.com, and thriveonline.com;
o publishers and distributors of traditional offline media, including
those targeted to healthcare professionals, many of which have
established or may establish web sites;
o general purpose consumer online services and portals which provide
access to healthcare-related content and services;
o public sector and non-profit web sites that provide healthcare
information without advertising or commercial sponsorships;
o vendors of healthcare information, products and services distributed
through other means, including direct sales, mail and fax messaging; and
o web search and retrieval services and other high-traffic web sites.
CHANGES IN THE HEALTHCARE INDUSTRY COULD ADVERSELY AFFECT OUR BUSINESS.
The healthcare industry is highly regulated and is subject to changing
political, economic and regulatory influences. These factors affect the
purchasing practices and operation of healthcare organizations. Changes in
current healthcare financing and reimbursement systems could cause us to make
unplanned modifications of applications or services, or result in delays or
cancellations of orders or in the revocation of endorsement of our applications
and services by healthcare participants. Federal and state legislatures have
periodically considered programs to reform or amend the U.S. healthcare system
at both the federal and state level. These programs may contain proposals to
increase governmental involvement in healthcare, lower reimbursement rates or
otherwise change the environment in which healthcare industry participants
operate. Healthcare industry participants may respond by reducing their
investments or postponing investment decisions, including investments in our
applications and services. We do not know what effect any proposals would have
on our business.
17
<PAGE> 18
THE TREND TOWARD CONSOLIDATION IN THE HEALTHCARE INDUSTRY COULD LEAD TO LOWER
OPERATING MARGINS.
Many healthcare providers are consolidating to create integrated healthcare
delivery systems with greater market power. These providers may try to use their
market power to negotiate price reductions for our applications and services. If
we were forced to reduce our prices, our operating margins would decrease. As
the healthcare industry consolidates, competition for customers will become more
intense and the importance of acquiring each customer will become greater.
GOVERNMENT REGULATION COULD ADVERSELY AFFECT OUR BUSINESS.
Our business is subject to government regulation. Existing as well as new
laws and regulations could adversely affect our business. Laws and regulations
may be adopted with respect to the Internet or other on-line services covering
issues such as:
o user privacy;
o pricing;
o content;
o copyrights;
o distribution; and
o characteristics and quality of products and services.
Regulation regarding patient confidentiality:
The applicability to the Internet of existing laws in various jurisdictions
governing issues such as property ownership, sales and other taxes, libel and
personal privacy is uncertain and may take years to resolve. Demand for our
applications and services may be affected by additional regulation of the
Internet. For example, until recently current Health Care Financing
Administration guidelines prohibited transmission of Medicare eligibility
information over the Internet.
We are subject to extensive regulation relating to the confidentiality and
release of patient records. Additional legislation governing the distribution of
medical records has been proposed at both the state and federal level. It may be
expensive to implement security or other measures designed to comply with any
new legislation. Moreover, we may be restricted or prevented from delivering
patient records electronically.
Emerging standards required by The Health Insurance Portability and
Accountability Act of 1996:
Legislation currently being considered at the federal level could affect
our business. For example, the Health Insurance Portability and Accountability
Act of 1996 mandates the use of standard transactions, standard identifiers,
security and other provisions by the year 2000. We are designing our platform
and applications to comply with these proposed regulations; however, until these
regulations become final, they could change, which could cause us to use
additional resources and lead to delays in order to revise our platform and
applications. In addition, our success depends on other healthcare participants
complying with these regulations.
Possible regulation by the U.S. Food and Drug Administration:
Some computer applications and software are considered medical devices and
are subject to regulation by the United States Food and Drug Administration, or
the FDA. We do not believe that our current applications or services are subject
to FDA regulation. We may expand our application and service offerings into
areas that subject us to FDA regulation. We have no experience in complying with
FDA regulations. We believe that complying with FDA regulations would be time
consuming, burdensome and expensive and could delay our introduction of new
applications or services.
WE MAY FACE LIABILITIES DUE TO ERRORS IN OUR PRODUCTS OR CONTENT ON OUR WEB
SITES.
Although we and our customers test our applications, they may contain
defects or result in system failures. In addition, our platform may experience
problems in security, availability, scalability or other critical features.
These defects or problems could result in the loss of or delay in generating
revenue, loss of market share, failure to achieve market acceptance, diversion
of development resources, injury to our reputation or increased insurance costs.
18
<PAGE> 19
Many of our strategic relationships and services agreements involve
providing critical information technology services to our clients' businesses.
Providing these services is complex because our clients have complex computing
system environments. If we fail to meet our clients' expectations, our
reputation could suffer and we could be liable for damages. In addition, patient
care could suffer and we could be liable if our systems fail to deliver correct
information in a timely manner. Our insurance may not protect us from this risk.
Finally, we could become liable if confidential information is disclosed
inappropriately.
Many of our contracts limit our liability arising from our errors; however,
these provisions may not be enforceable and may not protect us from liability.
While we have general liability insurance that we believe is adequate, including
coverage for errors and omissions, we may not be able to maintain this insurance
on reasonable terms in the future. In addition, our insurance may not be
sufficient to cover large claims and our insurer could disclaim coverage on
claims. If we are liable for an uninsured or underinsured claim or if our
premiums increase significantly, our financial condition could be materially
harmed.
In addition, we could be subject to third party claims based on the nature
and content of information supplied on our Web site by ourselves or by third
parties, including content providers, medical advisors or users. We could also
be subject to liability for content that may be accessible through out Web sites
linked from our Web sites or through content and information that may be posted
by users in chat rooms or bulletin boards. Even if these claims do not result in
liability to us, investigating and defending against these claims could be
expensive and time-consuming and could divert management's attention away from
operating the business.
OUR PROPRIETARY TECHNOLOGY MAY BE SUBJECTED TO INFRINGEMENT CLAIMS OR MAY BE
INFRINGED UPON.
Our intellectual property is important to our business. We could be subject
to intellectual property infringement claims as the number of our competitors
grows and the functionality of our applications overlaps with competitive
offerings. These claims, even if not meritorious, could be expensive and divert
our attention from operating our company. If we become liable to third parties
for infringing their intellectual property rights, we would be required to pay a
substantial damage award and to develop non-infringing technology, obtain a
license or cease selling the applications that contain the infringing
intellectual property. We may be unable to develop non-infringing technology or
obtain a license on commercially reasonable terms, or at all. In addition, we
may not be able to protect against misappropriation of our intellectual
property. Third parties may infringe upon our intellectual property rights, we
may not detect this unauthorized use and we may be unable to enforce our rights.
LENGTHY SALES AND IMPLEMENTATION CYCLES FOR OUR SOLUTIONS COULD ADVERSELY
AFFECT OUR REVENUE GROWTH.
A key element of our strategy is to market our solutions directly to large
healthcare organizations. We are unable to control many of the factors that will
influence our customers' buying decisions. We expect that the sales and
implementation process will be lengthy and will involve a significant technical
evaluation and commitment of capital and other resources by our customers. The
sale and implementation of our solutions are subject to delays due to our
customers' internal budgets and procedures for approving large capital
expenditures and deploying new technologies within their networks.
We will need to expend substantial resources to integrate our applications
with the existing legacy and client-server architectures of large healthcare
organizations. We have limited experience in integrating our applications with
large, complex architectures, and we may experience delays in the integration
process. These delays would, in turn, delay our ability to generate revenue from
these applications and could adversely affect our results of operations.
OUR BUSINESS WILL BE ADVERSELY AFFECTED IF WE CANNOT ATTRACT AND RETAIN KEY
PERSONNEL.
Our future operating results will substantially depend on our senior
management team and other key employees to manage changing business conditions
and to improve our technical, administrative, financial control and reporting
systems. We need to attract, integrate, motivate and retain additional highly
skilled technical people. In particular, we need to attract experienced
professionals capable of developing, selling and installing complex healthcare
information systems. We face intense competition for these people. Our executive
management team, including W. Michael Long, our Chief Executive Officer, is
critical to our success. We do not maintain key person life insurance for
anyone.
19
<PAGE> 20
LIQUIDITY AND CAPITAL RESOURCES
In February 1999, Healtheon completed the initial public offering of its
common stock and realized net proceeds from the offering of approximately $41.4
million. Prior to the offering, Healtheon had funded its operations since
inception primarily through the private placement of equity securities, through
which we had raised net proceeds of $106.2 million through December 31, 1998. We
have also financed our operations through equipment lease financing and bank
borrowings. As of June 30, 1999, we had outstanding equipment lease liabilities
of $4.8 million and notes payable of $0.9 million. As of June 30, 1999, we had
approximately $47.4 million of cash, cash equivalents and short-term
investments.
Cash used in operating activities was $24.3 million in the six months ended
June 30, 1999 compared to $9.1 million in the six months ended June 30, 1998.
The cash used during these periods was primarily attributable to net losses.
These losses were principally related to increased expenses as described more
fully above in Results of Operations.
Investments in property and equipment, excluding equipment acquired under
capital leases or through the issuance of common stock, were $7.3 million in the
six months ended June 30, 1999 and $2.7 million in the six months ended June 30,
1998. In the first six months of 1999, Healtheon used $16.4 million of cash to
purchase short-term investments and realized $22.7 million in cash from
maturities of its short-term investments. In the first six months of 1998,
Healtheon used $3.5 million of cash to purchase short-term investments and
realized $7.1 million in cash from maturities of its short-term investments.
Cash provided by financing activities was $41.5 million in the six months
ended June 30, 1999, primarily from the net proceeds of our initial public
offering of $41.4 million, as well as proceeds from exercises of employee stock
options, partially offset by payments totaling $1.4 million on capital lease
obligations and line of credit borrowings. Financing activities provided $2.8
million of cash in the six months ended June 30, 1998, resulting primarily from
proceeds from the issuance of preferred and common stock, offset in part by
payments on capital lease obligations.
As of June 30, 1999, we did not have any material commitments for capital
expenditures. Our principal commitments at June 30, 1999 consisted of
obligations under operating leases and capital leases and notes payable.
We currently anticipate that our available cash resources and credit
facilities will be sufficient to meet our presently anticipated working capital,
capital expenditure and business expansion requirements through the end of the
year. We may need to raise additional funds to support expansion, develop new or
enhanced applications and services, respond to competitive pressures, acquire
complementary businesses or technologies or take advantage of unanticipated
opportunities. However, with the completion of the merger with WebMD we will
have, on a combined basis, sufficient cash resources to meet our needs for at
least the next twelve months and for some extended time beyond that. Our future
liquidity and capital requirements will depend upon numerous factors, including
the success of our existing and new application and service offerings and
competing technological and market developments. We may be required to raise
additional funds through public or private financing, strategic relationships or
other arrangements. In the event the WebMD merger does not close, we may be
required to raise additional funds in the first quarter of 2000. There can be no
assurance that additional funding, if needed, will be available on terms
acceptable to us, or at all.
YEAR 2000 COMPLIANCE
Many currently installed computer systems and software products are unable
to distinguish between twentieth century dates and twenty-first century dates.
As a result, many companies' software and computer systems may need to be
upgraded or replaced to comply with these "Year 2000" requirements. Healtheon's
business is dependent on the operation of numerous systems that could
potentially be impacted by Year 2000 related problems. Those systems include,
among others: hardware and software systems used by Healtheon to deliver
services to its customers, including our proprietary software systems as well as
hardware and software supplied by third parties; communications networks, such
as the Internet and private intranets, which we depend on to provide electronic
transactions to our customers; the internal systems of our customers and
suppliers; the hardware and software systems we use internally in the management
of our business; and non-information technology systems and services we use in
our business, such as telephone systems and building systems.
Healtheon has reviewed the proprietary software systems we use to deliver
services to our customers. Although we believe that our internally developed
applications and systems are designed to be Year 2000 compliant, we utilize
third-party equipment and software that may not be Year 2000 compliant. In
January 1999, we acquired certain electronic laboratory results delivery
services from SmithKline Labs. SmithKline has warranted these services to be
20
<PAGE> 21
Year 2000 compliant. Also, two systems acquired by ActaMed, specifically SCAN
and ProviderLink, which together accounted for approximately 42% of our total
revenue in 1998 and 29% in the six months ended June 30, 1999, will require
modifications to become Year 2000 compliant. We have released an updated version
of SCAN which is Year 2000 compliant and we are in the process of deploying the
updated version of SCAN to our customers. ProviderLink has two versions. The DOS
version was made Year 2000 compliant and is currently being deployed to our
DOS-based customers. The Internet version is being modified to be Year 2000
compliant and we expect to begin deployment over the Internet in the second half
of 1999. We estimate the cost of these Year 2000 upgrades to be less than $1.0
million. In addition, our SCAN product is installed on approximately 4,650
Healtheon-owned workstations located in provider offices. Many of these
workstations are not Year 2000 compliant and we must upgrade or replace them. We
expect the costs of such upgrades or replacements to be less than $1.0 million.
However, we could experience delays and cost overruns in the development of
these upgrades, the upgrades could contain defects and we could experience
difficulties in getting our installed base of physicians to implement these
upgrades in a timely manner. If we experience these or other difficulties in
developing and deploying our Year 2000 upgrades, our revenues from SCAN,
ProviderLink and electronic laboratory delivery could be significantly reduced,
which could have a material adverse effect on our business, financial condition
and results of operations. Failure of third-party or of our equipment or
software to operate properly with regard to the Year 2000 and thereafter could
require us to incur unanticipated expenses to remedy any problems, which could
have a material adverse effect on our business, financial condition and results
of operations. In certain of our agreements, we warrant that our applications
and services are Year 2000 compliant. Failure of our applications and services
to be Year 2000 compliant could result in the termination of these agreements or
in liability for damages, either of which could have a material adverse effect
on our business, financial condition and results of operations. We do not
believe that the expenditures to upgrade our internal systems and applications
will have a material adverse effect on our business, financial condition and
results of operations.
Furthermore, the success of our efforts may depend on the success of other
healthcare participants in dealing with their Year 2000 issues. Many of these
organizations are not Year 2000 compliant, and the impact of widespread customer
failure on Healtheon's systems is difficult to determine. Customer difficulties
due to Year 2000 issues could interfere with healthcare transactions or
information, which might expose us to significant potential liability. If client
failures result in the failure of our systems, Healtheon's business, financial
condition and results of operations would be materially adversely affected.
Furthermore, the purchasing patterns of these customers or potential customers
may be affected by Year 2000 issues as companies expend significant resources to
become Year 2000 compliant. The costs of becoming Year 2000 compliant for
current or potential customers may result in reduced funds being available to
purchase and implement Healtheon's applications and services.
Healtheon, with the assistance of an independent consulting firm
specializing in Year 2000 issues, has completed a formal assessment of our Year
2000 exposure and is taking steps to address the identified points of exposure.
We expect to complete our Year 2000 remediation efforts in the second half of
1999. We are in the process of developing a contingency plan for handling Year
2000 problems that are not detected and corrected prior to their occurrence.
However, we are unable to make contingency plans if any significant number of
the computers constituting the Internet fail to properly process dates for the
year 2000 and there is a system-wide slowdown or breakdown. Any failure by us to
address any unforeseen Year 2000 issue could adversely affect our business,
financial condition and results of operations. Any interruption or significant
degradation of Internet operations, whether due to Year 2000 problems or
otherwise, could harm our business.
21
<PAGE> 22
- --------------------------------------------------------------------------------
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
- --------------------------------------------------------------------------------
INTEREST RATE SENSITIVITY
The primary objective of Healtheon's investment activities is to preserve
principal while at the same time maximizing the income we receive from our
investments without significantly increasing risk. Some of the securities that
we have invested in may be subject to market risk. This means that a change in
prevailing interest rates may cause the principal amount of the investment to
fluctuate. For example, if we hold a security that was issued with a fixed
interest rate at the then-prevailing rate and the prevailing interest rate later
rises, the principal amount of our investment will probably decline. To minimize
this risk, we maintain our portfolio of cash equivalents and short-term
investments in a variety of securities, including commercial paper, other
non-government debt securities and money market funds. In general, money market
funds are not subject to market risk because the interest paid on such funds
fluctuates with the prevailing interest rate. In addition, we invest in
relatively short-term securities. As of June 30, 1999, all of our investments
mature in less than three months.
The following table presents the amounts of our cash equivalents and
short-term investments that are subject to market risk by range of expected
maturity and weighted-average interest rates as of June 30, 1999. This table
does not include money market funds because those funds are not subject to
market risk.
<TABLE>
<CAPTION>
MATURING IN
THREE MONTHS FAIR
OR LESS VALUE
------------ --------
(DOLLARS IN THOUSANDS)
<S> <C> <C>
Included in cash and cash equivalents .. $ 31,899 $ 31,899
Weighted-average interest rate ....... 4.96%
Included in short-term investments ..... $ 11,017 $ 11,017
Weighted-average interest rates ...... 5.05%
</TABLE>
EXCHANGE RATE SENSITIVITY
Currently the majority of Healtheon's sales and expenses are denominated in
U.S. dollars and as a result we have experienced no significant foreign exchange
gains and losses to date. While we are conducting some transactions in foreign
currencies during 1999, we do not anticipate that foreign exchange gains or
losses will be significant. We have not engaged in foreign currency hedging
activities to date.
22
<PAGE> 23
- --------------------------------------------------------------------------------
PART II. OTHER INFORMATION
- --------------------------------------------------------------------------------
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits.
The Exhibits listed in the accompanying Exhibit Index on page 25 are
filed as part of this report.
(b) The following Reports on Form 8-K were filed during the quarter ended
June 30, 1999:
The Company filed a report on Form 8-K on April 23, 1999 regarding the
proposed acquisition of MEDE America Corporation.
The Company filed a report on Form 8-K on May 24, 1999 regarding the
proposed merger with WebMD, Inc.
In addition, the Company filed a report on Form 8-K on July 8, 1999
regarding the proposed acquisition of Greenberg News Networks, Inc.
23
<PAGE> 24
- --------------------------------------------------------------------------------
SIGNATURES
- --------------------------------------------------------------------------------
In accordance with the requirements of the Securities Exchange Act, the
Registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
HEALTHEON CORPORATION
Date: August 13, 1999 By: /s/ John L. Westermann III
-----------------------------------------
John L. Westermann III
Vice President, Chief Financial
Officer, Secretary and Treasurer
24
<PAGE> 25
- --------------------------------------------------------------------------------
EXHIBIT INDEX
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<S> <C>
10.1 Agreement and Plan of Reorganization dated May 20, 1999 by
and among Healtheon Corporation, Water Acquisition Corp.
and WebMD, Inc. (Incorporated by reference from
Healtheon's report on Form 8-K filed on May 20, 1999.)
10.2 Agreement and Plan of Merger dated June 30, 1999 by and
among Healtheon Corporation, Healtheon/WebMD Corporation,
WebMD, Inc., GNN Merger Corp. and Greenberg News Networks,
Inc. (Incorporated by reference from Healtheon's report on
Form 8-K filed on July 8, 1999.
27.1 Financial data schedule (EDGAR only)
</TABLE>
25
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM HEALTHEON'S
QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C> <C>
<PERIOD-TYPE> 6-MOS 6-MOS
<FISCAL-YEAR-END> DEC-31-1999 DEC-31-1998
<PERIOD-START> JAN-01-1999 JAN-01-1998
<PERIOD-END> JUN-30-1999 JUN-30-1998
<CASH> 36,241 11,075
<SECURITIES> 11,112 1,726
<RECEIVABLES> 11,623 5,642
<ALLOWANCES> 0 0
<INVENTORY> 0 0
<CURRENT-ASSETS> 61,442 18,796
<PP&E> 32,182 15,562
<DEPRECIATION> (13,921) (5,602)
<TOTAL-ASSETS> 108,028 49,410
<CURRENT-LIABILITIES> 23,646 16,236
<BONDS> 0 0
0 0
0 0
<COMMON> 7 5
<OTHER-SE> 81,766 31,710
<TOTAL-LIABILITY-AND-EQUITY> 108,028 49,410
<SALES> 0 0
<TOTAL-REVENUES> 40,253 20,653
<CGS> 0 0
<TOTAL-COSTS> 0 0
<OTHER-EXPENSES> 77,569 42,480
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> 254 251
<INCOME-PRETAX> (36,134) (22,331)
<INCOME-TAX> 0 0
<INCOME-CONTINUING> (36,134) (22,331)
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> (36,134) (22,331)
<EPS-BASIC> (0.55) (1.27)
<EPS-DILUTED> (0.55) (1.27)
</TABLE>
